Liver transplantation for malignancy: Current treatment strategies and future perspectives

Table 3 Liver transplantation for hepatoblastoma

Database	Author	Year	Year of LT	n	Age of patients at LT	% female	Median FU	Overall survival in %			LDLT
								1 yr	3 yr	5 yr
SIOPEL-3HR	Zsiros	2010	1998-2004	31	< 16 yr (median 21 mo)	NR	54 mo	NR	75%	NR	NR
Chicago/Toronto	Browne	2008	1990-2004	14	18 mo-13 yr (mean 57 mo)	36	46 mo	71% @ 46 mo			NR
London	Faraj	2008	1993-2007	25	0.5-10 yr (median 2.5 yr)	32	6.8 yr	91		78	28%
Stanford	Beaunoyer	2007	1988-2006	15	0.3-9.7 yr (mean 2.6 yr)	47	3.3 ± 3.5 yr	87	87	87	0
Spain	Avila	2006		11	6 mo-14 yr			91	91	82	25%
UNOS review	Austin	2006	1987-2004	135	2.9 ± 2.5 yr	38		79		69
Texas	Mejia	2005	1995-2003	10	mean 5.8 yr	50	Mean 10.8 yr	70% @ last FU (mean 10.8 yr)			20%
Kyoto	Kasahara	2005	1990-2004	14	NR	NR	NR	78.6	NR	65.5	100%
SIOPEL-1	Otte	2004	1990-1994	12	1.25-11.6 yr (median 3.8 yr)	42	117 mo	NR	NR	75	NR
Dallas	Molmenti	2002	1984-2000	9	6 mo-16 yr (mean 6.4 yr)	44	NR	NR	67%	NR	0%
France	Chardot	2002	1998-1999	4	10-60 mo (mean 17 mo)	NR	NR	75% at last FU (13-24 mo)			100%
Birmingham	Pimpalwar	2002	1991-2000	12	0.15-8.78 yr at diag. (median 1.32 yr)	NR	NR	NR	93%	83%	0
Pittsburgh	Reyes	2000	1989-1998	12	NR	NR	NR	92	92	83	0

LT: Liver transplantation; FU: Follow-up; LDLT: Living-donor liver transplantation; NR: Not reported; UNOS: United Network for Organ Sharing.